PR: WILEX AG: Subsidiary Heidelberg Pharma Exercises Option on BCMA Antibodies of the Max Delbrück Center and Signs License Agreement
- PDF File: images/files//2022/20170125_pm_lizenz-max-delbruck-zentrum_eng_final.pdf
- Datum: Wednesday, 25 January 2017 11:29
- Erstellt am .
- Geändert am .
- Aufrufe: 1328